Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
1 participants
OBSERVATIONAL
2011-02-28
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A prospective cohort study of patients who receive EZG under circumstances not indicated in the product label within the HIRD will also be conducted. Following the launch of EZG, epilepsy patients initiating AED monotherapy with EZG as well as non-epilepsy patients initiating EZG for another disease will be followed until the earliest of an episode of UR, change in their AED regimen (if applicable), end of follow-up, or end of study. The incidence of UR during exposure to EZG under circumstances not indicated in the product label will be described. A descriptive analysis of the patients will also be included.
To meet the other secondary objective, non-EZG AED monotherapy users will be identified in the prospective cohort and incidence of UR will be calculated to determine if there is a difference in UR risk between monotherapy and polytherapy AED use.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In January 2010, the FDA accepted the new drug application (NDA) for EZG for adjunctive treatment of epilepsy in adults with partial-onset seizures. US market entry is anticipated by 2011. EZG is the first potassium channel opener to reach late stage clinical development for the treatment of epilepsy. EZG's anticonvulsant properties are primarily mediated by opening or activating neuronal voltage-gated potassium channels. The efficacy and safety of EZG as part of polytherapy AED regimens in adults with refractory partial-onset seizures has been demonstrated in one Phase II and two Phase III double-blind, placebo-controlled trials: RESTORE 1 and 2.
In the Phase II study, 399 patients were randomized to four treatment arms (placebo, 600, 900, and 1200 mg/day EZG). The median change from baseline seizure frequency was 13.1% for the placebo group; in comparison, the median change was 23.4% for 600 mg/day, 29.3% for 900 mg/day (p=0.0387), and 35.2% for 1200 mg/day (p=0.0024). RESTORE 1 was conducted in the US and had two arms (placebo and 1200 mg/day EZG), while RESTORE 2 was conducted mainly in Europe and Australia with three different arms (placebo, 600, and 900 mg/day EZG). In RESTORE 1 (n=301), the median reduction in seizure frequency among patients using 1200 mg/day EZG (n=151) was 44% compared with 18% among placebo users (n=150; p\<0.001). In RESTORE 2, a significant reduction in partial seizure frequency was found in both EZG doses vs. placebo (p\<0.001): 28% for 600 mg/day, 40% for 900 mg/day, and 16% for placebo.During these trials EZG was generally well tolerated; most adverse events (AEs) were mild or moderate with central nervous system (CNS) related AEs (dizziness, somnolence and fatigue) being most common. However, among non-CNS events, an increased incidence of bladder-related AEs, including UR, relative to placebo was observed with EZG, primarily with 1200 mg/day. Among the patients in EZG arms from all trials (n=813), 0.9% experienced UR compared with 0.5% in the placebo arms (n=427). In addition 5% of patients in the EZG arms compared with 3% of patients in the placebo arms experienced urinary symptoms, including dysuria, urinary hesitancy, and UR.
There are concerns that these AEs may reflect the inhibition of bladder contractility secondary to EZG's effects on KCNQ (Kv7) voltage-gated potassium channels in the detrusor muscle of the bladder. However, the limited number of patients exposed to EZG during trials suggests that the risk of UR associated with exposure to EZG has to date been poorly quantified.
A post-marketing safety surveillance study using a US health insurance claims database coupled with medical records review will be implemented to determine the risk of UR associated with exposure to AED polytherapy regimens containing EZG in a real-world setting. The risk of UR among epilepsy patients treated with EZG AED polytherapy will be compared to the risk among epilepsy patients treated with non-EZG AED polytherapy. In addition, both EZG and non-EZG AED polytherapy users will be described in terms of their demographic characteristics, concomitant AED use, co-morbidities, use of medications potentially associated with UR, and medical conditions pre-disposing to UR. Secondarily, off-label usage of EZG will be monitored and described. In addition, the risk of UR among epilepsy patients treated with non-EZG AED monotherapy will be determined.
The primary objective of the study is to quantify the risk of UR associated with exposure to EZG AED polytherapy in a real-world setting. Specific aims include the following:1) to describe patients receiving EZG and non-EZG AED polytherapy in terms of demographics, concomitant AED use, co-morbidities/past medical history, use of medications potentially associated with UR, and medical conditions associated with UR; 2) to determine the magnitude of the risk and time to onset of UR associated with post-marketing use of EZG AED polytherapy, and to determine the incremental risk compared with non-EZG AED polytherapy use; and 3) to determine whether the risk and time to onset of UR associated with non-EZG monotherapy use.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with urinary retention
Patients with urinary retention
Non-EZG containing AED polytherapy
AED polytherapy without EZG
EZG containing AED polytherapy
AED polytherapy including EZG
Non-EZG AED monotherapy
AED monotherapy without EZG
EZG AED monotherapy
Any off-label use of EZG as monotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-EZG containing AED polytherapy
AED polytherapy without EZG
EZG containing AED polytherapy
AED polytherapy including EZG
Non-EZG AED monotherapy
AED monotherapy without EZG
EZG AED monotherapy
Any off-label use of EZG as monotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with at least one medical claim carrying an ICD-9 code for epilepsy. The following ICD-9 codes will be used to identify patients with epilepsy:
* 345 Epilepsy and recurrent seizures
* 780.3 Convulsions
* 780.39 Other convulsions
* Patients initiating a new AED monotherapy\* or polytherapy\*\* following the launch of EZG.
* At least 6 months of continuous healthcare plan enrolment before initiation of the new AED (monotherapy or polytherapy) following the launch of EZG. This will allow an assessment of baseline co-morbidities and concomitant medication use.
* Aged ≥18 years at initiation of the new AED (monotherapy or polytherapy).
* Prospective Cohort (non-indicated use)
* Epilepsy patients initiating EZG AED monotherapy
* Patients \<18 years old initiating EZG for epilepsy
* Patients initiating EZG for any reason other than epilepsy
* Patients initiating EZG AED polytherapy with less than six months of continuous healthcare enrolment who were excluded from the cohort described under the primary objective
* Retrospective Cohort
* Patients with at least one medical claim carrying an ICD-9 code for epilepsy in the three year period preceding the launch of EZG. The following ICD-9 codes will be used to identify patients with epilepsy:
* 345 Epilepsy and recurrent seizures
* 780.3 Convulsions
* 780.39 Other convulsions
* Patients initiating a new AED monotherapy\* or polytherapy\*\* regimen in the three year period preceding the launch of EZG.
* At least 6 months of continuous healthcare plan enrolment before initiation of the new AED regimen (monotherapy or polytherapy) during the three year period preceding the launch of EZG. This will allow an assessment of baseline co-morbidities and concomitant medication use.
* Aged ≥18 years at initiation of the new AED (monotherapy or polytherapy).
* This will include patients substituting an AED monotherapy. \*\*This will include patients switching from a monotherapy to polytherapy regimen and those substituting an AED within an existing polytherapy regimen.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WEUKSTV4551
Identifier Type: OTHER
Identifier Source: secondary_id
EPI40621
Identifier Type: OTHER
Identifier Source: secondary_id
115981
Identifier Type: -
Identifier Source: org_study_id